KR20050005438A - 활성 성분 마이크로캡슐의 경구 현탁액 - Google Patents
활성 성분 마이크로캡슐의 경구 현탁액 Download PDFInfo
- Publication number
- KR20050005438A KR20050005438A KR10-2004-7016079A KR20047016079A KR20050005438A KR 20050005438 A KR20050005438 A KR 20050005438A KR 20047016079 A KR20047016079 A KR 20047016079A KR 20050005438 A KR20050005438 A KR 20050005438A
- Authority
- KR
- South Korea
- Prior art keywords
- active ingredient
- microcapsules
- suspension
- liquid phase
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Abstract
Description
샘플 번호 | 5ml의 현탁액에 대한 활성 성분 함량(g) |
1 | 2.58 |
2 | 2.60 |
3 | 2.62 |
4 | 2.59 |
5 | 2.60 |
6 | 2.63 |
Claims (20)
- (아목시실린을 제외한) 1종 이상의 활성 성분을 변형 방출시키고 경구 투여를 위한 것인, 수성 액체 상 중의 마이크로캡슐(microcapsule) 현탁액에 있어서, 다음을 특징으로 하는 마이크로캡슐 현탁액.■ (아목시실린을 제외한) 1종 이상의 활성 성분을 포함하는 코어(core) 및 필름 코팅으로 각각 구성된 복수의 마이크로캡슐을 포함하는데, 필름 코팅은:● 코어에 도포되고,● 활성 성분(들)의 변형 방출을 조절하며,● 하기 부류 A, B 및 C 중 하나에 상응하는 조성을 갖는다:⇒부류 A◆ 1A - 위장관 유체에 불용성이며, 코팅 조성물의 총 중량을 기준으로 하여 50 내지 90 및 바람직하게는 50 내지 80 건조중량%의 양으로 존재하며, 1종 이상의 수불용성 셀룰로스 유도체로 구성된 1종 이상의 필름 형성 중합체(P1);◆ 2A - 코팅 조성물의 총 중량을 기준으로 하여 2 내지 25 및 바람직하게는 5 내지 15 건조중량%의 양으로 존재하며, 1종 이상의 폴리아크릴아미드 및(또는) 폴리-N-비닐아미드 및(또는) 폴리-N-비닐락탐으로 구성된 1종 이상의 질소 포함 중합체(P2);◆ 3A - 코팅 조성물의 총 중량을 기준으로 하여 2 내지 20 및 바람직하게는 4 내지 15 건조중량%의 양으로 존재하며, 1종 이상의 하기 화합물: 글리세롤 에스테르, 프탈레이트, 시트레이트, 세바케이트, 세틸 알콜 에스테르 및 피마자유로 구성된 1종 이상의 가소제;◆ 4A - 코팅 조성물의 총 중량을 기준으로 하여 2 내지 20 및 바람직하게는 4 내지 15 건조중량%의 양으로 존재하며, 음이온성 계면활성제 및(또는) 비이온성 계면활성제 및(또는) 윤활제로부터 선택된 1종 이상의 계면활성제 및(또는) 윤활제, 상기 작용제는 상기 화합물 중 단지 1종 또는 혼합물을 포함할 수 있다;⇒부류 B∼ 1B - 중성 pH에서 이온화된 기를 가지며 바람직하게는 셀룰로스 유도체로부터 선택되는 1종 이상의 친수성 중합체;∼ 2B - A와는 다른 1종 이상의 소수성 화합물;⇒부류 C◆ 1C - 위장관 유체에 불용성인 1종 이상의 필름 형성 중합체;◆ 2C - 1종 이상의 수용성 중합체;◆ 3C - 1종 이상의 가소제;◆ 4C - 바람직하게는 하기 군의 화합물로부터 선택되는 임의의 1종 이상의 계면활성제/윤활제:∼ 음이온성 계면활성제;∼ 및(또는) 비이온성 계면활성제,■ 그리고 액체 상은 활성 성분(들)으로 포화되어 있거나 마이크로캡슐과 접촉 시에 포화된다.
- 제 1 항에 있어서, 코팅 조성물의 성분이 선택되는 상기 부류 A, B 및 C가 다음과 같은 것을 특징으로 하는 현탁액.⇒부류 A◆ 1A - 에틸 셀룰로스 및(또는) 셀룰로스 아세테이트;◆ 2A - 폴리아크릴아미드 및(또는) 폴리비닐피롤리돈;◆ 3A - 피마자유;◆ 4A - 지방산, 바람직하게는 스테아르산 및(또는) 올레산의 알칼리금속 또는 알칼리토금속염, 폴리에톡실화 소르비탄 에스테르, 폴리에톡실화 피마자유 유도체, 스테아레이트, 바람직하게는 칼슘, 마그네슘, 알루미늄 또는 아연 스테아레이트, 스테아릴푸마레이트, 바람직하게는 나트륨 스테아릴푸마레이트, 또는 글리세롤 베헤네이트(이들은 개별적으로 또는 서로간의 혼합물로서 선택됨);⇒부류 B◆ 1B∼ 셀룰로스 아세테이트-프탈레이트;∼ 히드록시프로필 메틸 셀룰로스 프탈레이트;∼ 히드록시프로필 메틸 셀룰로스 아세테이트-숙시네이트;∼ (메트)아크릴산/(메트)아크릴산 알킬 (메틸) 에스테르 공중합체;∼ 및 그의 혼합물;◆ 2B∼ 수소화 식물성 왁스;∼ 트리글리세라이드;∼ 동물성 및 식물성 지방(밀랍, 경랍 등);∼ 및 그의 혼합물.⇒부류 C◆ 1C∼ 수불용성 셀룰로스 유도체, 특히 바람직하게는 에틸 셀룰로스 및(또는) 셀룰로스 아세테이트;∼ 아크릴 유도체;∼ 폴리비닐 아세테이트;∼ 및 그의 혼합물;◆ 2C∼ 수용성 셀룰로스 유도체;∼ 폴리아크릴아미드;∼ 폴리-N-비닐아미드;∼ 폴리-N-비닐락탐;∼ 폴리비닐 알콜(PVA);∼ 폴리옥시에틸렌(POE);∼ 폴리비닐피롤리돈(PVP)(이것이 바람직하다);∼ 및 그의 혼합물;◆ 3C∼ 글리세롤 및 그의 에스테르, 바람직하게는 하기 아군으로부터 선택되는 것들: 아세틸화 글리세라이드, 글리세롤 모노스테아레이트, 글리세릴 트리아세테이트 및 글리세롤 트리부티레이트;∼ 프탈레이트, 바람직하게는 하기 아군으로부터 선택되는 것들: 디부틸 프탈레이트, 디에틸 프탈레이트, 디메틸 프탈레이트 및 디옥틸 프탈레이트;∼ 시트레이트, 바람직하게는 하기 아군으로부터 선택되는 것들: 아세틸트리부틸 시트레이트, 아세틸트리에틸 시트레이트, 트리부틸 시트레이트 및 트리에틸 시트레이트;∼ 세바케이트, 바람직하게는 하기 아군으로부터 선택되는 것들: 디에틸 세바케이트 및 디부틸 세바케이트;∼ 아디페이트;∼ 아젤레이트;∼ 벤조에이트;∼ 식물성 유;∼ 푸마레이트, 바람직하게는 디에틸 푸마레이트;∼ 말레이트, 바람직하게는 디에틸 말레이트;∼ 옥살레이트, 바람직하게는 디에틸 옥살레이트;∼ 숙시네이트, 바람직하게는 디부틸 숙시네이트;∼ 부티레이트;∼ 세틸 알콜 에스테르;∼ 살리실산;∼ 트리아세틴;∼ 말로네이트, 바람직하게는 디에틸 말로네이트;∼ 쿠틴;∼ 피마자유(이것이 특히 바람직하다);∼ 및 그의 혼합물;◆ 4C∼ 지방산, 바람직하게는 스테아르산 및(또는) 올레산의 알칼리금속 또는 알칼리토금속염;∼ 폴리에톡실화 유, 바람직하게는 폴리에톡실화 수소화 피마자유;폴리옥시에틸렌/폴리옥시프로필렌 공중합체;폴리에톡실화 소르비탄 에스테르;폴리에톡실화 피마자유 유도체;스테아레이트, 바람직하게는 칼슘, 마그네슘, 알루미늄 또는 아연 스테아레이트;스테아릴푸마레이트, 바람직하게는 나트륨 스테아릴푸마레이트;글리세롤 베헤네이트;및 그의 혼합물.
- 제 1 항 또는 제 2 항에 있어서, 필름 코팅이 단일 층으로 이루어지는 것을 특징으로 하는 현탁액.
- 제 1 항에 있어서,-30 내지 95 중량%, 바람직하게는 60 내지 85 중량%의 액체 상(유리하게는 물);-및 5 내지 70 중량%, 바람직하게는 15 내지 40 중량%의 마이크로캡슐을 포함하는 것을 특징으로 하는 현탁액.
- 제 1 항에 있어서, 활성 성분(들)에 대한 용매 액체 상(바람직하게는 물)의 양이, 마이크로캡슐로부터 유래된 용해된 활성 성분(들)의 비율이 마이크로캡슐에 포함된 활성 성분(들)의 총 중량을 기준으로 하여 15 중량% 이하, 바람직하게는 5 중량% 이하이도록 하는 것을 특징으로 하는 현탁액.
- 제 1 항에 있어서, 마이크로캡슐이 액체 상에 혼입된 후 액체 상이 적어도 부분적으로, 바람직하게는 완전히 활성 성분(들)로 포화되는 것을 특징으로 하는 현탁액.
- 제 6 항에 있어서, 마이크로캡슐 중에 포함된 활성 성분(들)이 액체 상을 포화시키는 것을 특징으로 하는 현탁액.
- 제 1 항에 있어서, 마이크로캡슐이 액체 상에 혼입되기 전 액체 상이 적어도 부분적으로, 바람직하게는 완전히 비캡슐화 활성 성분(들)에 의해 활성 성분(들)로 포화되는 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 8 항 중 어느 한 항에 있어서, 마이크로캡슐이 1000 미크론 이하, 바람직하게는 200 내지 800 미크론, 특히 바람직하게는 200 내지 600 미크론의 입자 크기를 갖는 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 9 항 중 어느 한 항에 있어서, 필름 코팅이 코팅된 마이크로캡슐 총 중량의 1 내지 50%, 바람직하게는 5 내지 40%인 것을 특징으로 하는 현탁액.
- 제 10 항에 있어서, 문헌[European Pharmacopoeia 3rd edition]에 따른 유형 II 장치를 사용해서, pH 6.8의 인산염 완충액 매질 중, 37℃의 온도에서 측정된 시험관 내 방출 프로파일(profile)이 다음과 같은 것을 특징으로 하는 현탁액.▶ 용해 시험의 최초 15분 동안 방출된 활성 성분(들)의 비율 PI은 다음과 같다:PI<15,바람직하게는 PI<5;▶ 나머지 활성 성분(들)은 활성 성분 중량의 50%의 방출 시간(t1/2)이 다음과 같이 한정되도록 하는 시간동안 방출된다(시간):0.5<t1/2 <30,바람직하게는 0.5<t1/2 <20
- 제 1 항 내지 제 11 항 중 어느 한 항에 있어서,-마이크로캡슐을 용매 (바람직하게는 수성) 상 중에 현탁한 직후에, 문헌[European Pharmacopoeia 3rd edition]에 따른 유형 II 장치를 사용해서, pH 6.8의 인산염 완충액 매질 중, 온도 37℃에서 얻은 초기 시험관 내 방출 프로파일 Pf1,-및 마이크로캡슐을 용매 (바람직하게는 수성) 상 중에 현탁하고 10일 후에, 문헌[European Pharmacopoeia 3rd edition]에 따른 유형 II 장치를 사용해서, pH 6.8의 인산염 완충액 매질 중, 온도 37℃에서 얻은 시험관 내 방출 프로파일 Pf10이 유사한 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 12 항 중 어느 한 항에 있어서, pH가 임의로 산성 또는 중성인 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 13 항 중 어느 한 항에 있어서, 1종 이상의 유동학(rheology) 변형제를 포함하는 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 14 항 중 어느 한 항에 있어서, 용매 (바람직하게는 수성) 액체 상 중의 활성 성분(들)의 용해도를 변경하기 위한 1종 이상의 작용제를 포함하는 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 15 항 중 어느 한 항에 있어서, 계면활성제, 착색제, 분산제, 보존제, 맛 개선제, 향료, 감미료, 항산화제 및 그의 혼합물을 포함하는 군으로부터 선택된 1종 이상의 첨가제를 포함하는 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 16 항 중 어느 한 항에 있어서, 활성 성분(들)이 하기 부류의 활성 물질: 항궤양약, 당뇨병약, 항응고제, 항혈전제, 저지질혈증제, 항부정맥제, 혈관확장제, 항협심증약, 항고혈압제, 혈관보호제, 분만 촉진제, 분만 유도제 및 억제제, 피임약, 항생제, 항진균제, 항바이러스제, 항암제, 항염증제, 진통제, 항간질제, 항파킨슨병약, 신경이완제, 수면제, 항불안제, 정신자극제, 항편두통약, 항우울제, 진해제, 항히스타민제 및 항알레르기제 중 1종 이상에 속하는 것을 특징으로 하는 현탁액.
- 제 17 항에 있어서, 활성 성분이 하기 화합물: 펜톡시필린, 프라조신, 아시클로비르, 니페디핀, 딜티아젬, 나프록센, 이부프로펜, 플루르비프로펜, 케토프로펜, 페노프로펜, 인도메타신, 디클로페낙, 펜티아작, 오에스트라디올 발러레이트, 메토프롤올, 술피리드, 캡토프릴, 시메티딘, 지도부딘, 니카르디핀, 테르페나딘, 아테놀올, 살부타몰, 카르바마제핀, 라니티딘, 에나라프릴, 심바스타틴, 플루옥세틴, 알프라졸암, 파모티딘, 간시클로비르, 팜시클로비르, 스피로노락톤, 5-아사, 퀴니딘, 페린도프릴, 모르핀, 펜타조신, 메트포르민, 파라세타몰, 오메프라졸, 메토클로프라미드, 아테놀올, 살부타몰 모르핀, 베라파밀, 에리트로마이신, 카페인, 푸로세미드, 세팔로스포린, 몬텔루카스트, 발라시클로비르, 아스코르브산염, 디아제팜, 테오필린, 시프로플록사신, 반코마이신, 아미노글리코시드, 페니실린(아목시실린 제외) 및 그의 혼합물로부터 선택되는 것을 특징으로 하는 현탁액.
- 제 1 항 내지 제 18 항 중 어느 한 항에 따른 현탁액을 포함하는 것을 특징으로 하는 약품.
- 제 1 항 내지 제 18 항 중 어느 한 항에 따른 현탁액 제조를 위한 키트를 포함하는 것을 특징으로 하는 약품에 있어서, 키트가 다음을 포함하는 약품.-일단 두 고체 및 액체 상이 접촉될 때 액체 상을 활성 성분(들)으로 포화시키기 위한 활성 성분(들)을 포함하는 실질적으로 건조한 형태의 마이크로캡슐;-및(또는) 변형 방출에 필수적인 투여량의 활성 성분(들)을 포함하는 실질적으로 건조한 형태의 마이크로캡슐과, 일단 활성 성분(들)의 포화 투여량 및 액체상이 접촉될 때 액체 상을 활성 성분(들)으로 포화시키는데 필수적이고 충분한 투여량의 즉시 방출 비코팅 활성 성분의 혼합물;-및 액체 상 및(또는) 그의 제조에 유용한 성분의 적어도 일부, 및(또는) 현탁액 제조 프로토콜(protocol).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204409 | 2002-04-09 | ||
FR02/04409 | 2002-04-09 | ||
FR02/10847 | 2002-09-02 | ||
FR0210847A FR2843881B1 (fr) | 2002-09-02 | 2002-09-02 | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
PCT/FR2003/001096 WO2003084518A2 (fr) | 2002-04-09 | 2003-04-07 | Suspension orale de microcapsules de principes actifs |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050005438A true KR20050005438A (ko) | 2005-01-13 |
KR101061351B1 KR101061351B1 (ko) | 2011-08-31 |
Family
ID=28793279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047016079A KR101061351B1 (ko) | 2002-04-09 | 2003-04-07 | 활성 성분 마이크로캡슐의 경구 현탁액 |
Country Status (16)
Country | Link |
---|---|
US (5) | US7906145B2 (ko) |
EP (1) | EP1492511B3 (ko) |
JP (1) | JP4732696B2 (ko) |
KR (1) | KR101061351B1 (ko) |
CN (1) | CN100553625C (ko) |
AT (1) | ATE419840T1 (ko) |
AU (1) | AU2003246792B2 (ko) |
BR (1) | BRPI0309142C1 (ko) |
CA (1) | CA2480826C (ko) |
DE (1) | DE60325709D1 (ko) |
ES (1) | ES2320438T7 (ko) |
HK (1) | HK1079448A1 (ko) |
IL (2) | IL164222A0 (ko) |
MX (1) | MXPA04009968A (ko) |
PT (1) | PT1492511E (ko) |
WO (1) | WO2003084518A2 (ko) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
PT1492511E (pt) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s) |
FR2841140B1 (fr) * | 2002-06-24 | 2004-10-01 | Servier Lab | Microcapsules pour la liberation retardee et controlee du perindopril |
FR2842736B1 (fr) * | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
FR2842735B1 (fr) * | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
FR2881652B1 (fr) * | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
JP2008530185A (ja) * | 2005-02-21 | 2008-08-07 | フラメル・テクノロジー | ロサルタンの経口医薬剤形態 |
FR2882259A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan |
FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
FR2884145A1 (fr) * | 2005-04-06 | 2006-10-13 | Flamel Technologies Sa | Forme pharmaceutique orale de losartan |
GB0507167D0 (en) | 2005-04-08 | 2005-05-18 | Glaxosmithkline Consumer Healt | Composition |
BRPI0609910A2 (pt) * | 2005-05-10 | 2010-05-11 | Novartis Ag | composições farmacêuticas de famciclovir de liberação modificada |
WO2007022105A2 (en) * | 2005-08-12 | 2007-02-22 | Rubicon Research Pvt. Ltd. | Stable pharmaceutical compositions, processes for making the same, and methods of their use |
CN101400343B (zh) | 2006-03-16 | 2012-01-11 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
CA2782285A1 (en) * | 2009-12-02 | 2011-06-09 | Luigi Mapelli | Fexofenadine microcapsules and compositions containing them |
EP2515882A2 (en) * | 2009-12-22 | 2012-10-31 | Abbot Healthcare Private Limited | Controlled release pharmaceutical composition |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
US9254281B2 (en) * | 2011-09-12 | 2016-02-09 | Wright State University | Composition and method for the treatment of neurodegeneration |
CN102579398A (zh) * | 2011-12-31 | 2012-07-18 | 沈阳药科大学 | 一种具有掩盖药物不良口味作用的肠溶微囊及制备方法 |
CN102552163B (zh) * | 2012-01-05 | 2013-12-04 | 金陵药业股份有限公司 | 一种酒石酸美托洛尔缓释微丸及其制备方法 |
EP2884961B1 (en) | 2012-08-15 | 2019-03-06 | Tris Pharma Inc. | Methylphenidate extended release chewable tablet |
CA2988431C (en) | 2013-03-12 | 2020-02-11 | Panacea Biomatx, Inc. | Method and system for making customized formulations for individuals |
CA2947528C (en) | 2014-05-01 | 2023-09-05 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
EP3137057B1 (en) * | 2014-05-01 | 2020-09-09 | Sun Pharmaceutical Industries Ltd | Extended release liquid compositions of metformin |
US20180104197A9 (en) * | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
JP6335692B2 (ja) * | 2014-07-08 | 2018-05-30 | ライオン株式会社 | 液体経口製剤 |
RU2017106010A (ru) | 2014-07-30 | 2018-08-28 | Сан Фармасьютикал Индастриз Лимитед | Двухкамерная упаковка |
JP2017524053A (ja) * | 2014-08-15 | 2017-08-24 | ダウ グローバル テクノロジーズ エルエルシー | エチルセルロース分散体及び粉末 |
MA41124A (fr) * | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
MA43132A (fr) * | 2015-10-30 | 2018-09-05 | Cmp Dev Llc | Compositions aqueuses de spironolactone |
US10493083B2 (en) * | 2015-10-30 | 2019-12-03 | Cmp Development Llc | Spironolactone aqueous compositions |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
KR102393596B1 (ko) | 2016-04-22 | 2022-05-04 | 리셉터 홀딩스, 인크. | 속효성 식물-계 의약 화합물 및 영양 보충제 |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
GB201716716D0 (en) | 2017-10-12 | 2017-11-29 | Univ Of Hertfordshire Higher Education Corporation | Method for coating particles |
WO2019126218A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
WO2019126215A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
WO2020011938A1 (en) | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoids for the topical treatment of autoimmune gastritis |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US20220133647A1 (en) * | 2019-03-01 | 2022-05-05 | Avadel Legacy Pharmaceuticals, Llc | Liquid guaifenesin compositions with stable extended release profiles |
US20210275461A1 (en) | 2019-09-12 | 2021-09-09 | Nulixir Inc. | Particles for administration of active ingredients and methods of making the same |
CN112370437B (zh) * | 2020-10-20 | 2022-10-21 | 好医生药业集团有限公司 | 一种阿莫西林胶囊及其制备方法 |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (289)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029884A (en) | 1971-03-18 | 1977-06-14 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
US3927216A (en) | 1971-06-01 | 1975-12-16 | Icn Pharmaceuticals | 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections |
US3864483A (en) | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US3914415A (en) | 1973-06-14 | 1975-10-21 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
US3914414A (en) | 1973-06-14 | 1975-10-21 | Abbott Lab | Method of increasing coronary pO{HD 2 {B in mammals |
US3892769A (en) | 1973-07-20 | 1975-07-01 | Merck & Co Inc | Acetaminophen esters of aryl salicylic acids |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
DE2417465A1 (de) | 1974-04-10 | 1975-10-30 | Lester R Wellman | Vorrichtung zum oeffnen und wiederverschliessen eines dicht verschlossenen flexiblen behaelters |
US3966917A (en) | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
DE2530563C2 (de) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
FR2313915A1 (fr) | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US4308251A (en) | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
JPS6056122B2 (ja) | 1980-05-21 | 1985-12-09 | 塩野義製薬株式会社 | 徐放性製剤 |
US4321253A (en) | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
US4454309A (en) | 1980-11-12 | 1984-06-12 | Tyndale Plains-Hunter, Ltd. | Polyurethane polyene compositions |
JPS57197214A (en) | 1981-05-29 | 1982-12-03 | Tanabe Seiyaku Co Ltd | Rapid-releasing microcapsule and its preparation |
US4443549A (en) | 1981-10-19 | 1984-04-17 | Molecular Genetics, Inc. | Production of monoclonal antibodies against bacterial adhesins |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4507276A (en) | 1982-08-20 | 1985-03-26 | Bristol-Myers Company | Analgesic capsule |
US4461759A (en) | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
US4833905A (en) | 1983-06-03 | 1989-05-30 | Micromatic Textron Inc. | Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
ATE60340T1 (de) | 1984-10-19 | 1991-02-15 | Battelle Memorial Institute | Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten. |
EP0198769A3 (en) | 1985-04-12 | 1987-09-02 | Forest Laboratories, Inc. | Floating sustained release therapeutic compositions |
EP0202027A1 (en) | 1985-04-18 | 1986-11-20 | Sumitomo Chemical Company, Limited | A herbicidal composition |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
LU85943A1 (fr) | 1985-06-12 | 1987-01-13 | Galephar | Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation |
IT1185177B (it) * | 1985-07-03 | 1987-11-04 | Metalvuoto Films Spa | Dispositivo per realizzare film plastici metallizzati presentanti zone ben delimitate prive di metallizzazione |
US5002551A (en) | 1985-08-22 | 1991-03-26 | Johnson & Johnson Medical, Inc. | Method and material for prevention of surgical adhesions |
US4693896A (en) | 1985-10-07 | 1987-09-15 | Fmc Corporation | Ethylcellulose-coated, gastric-disintegrable aspirin tablet |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
AU591248B2 (en) | 1986-03-27 | 1989-11-30 | Kinaform Technology, Inc. | Sustained-release pharaceutical preparation |
SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
WO1987007833A1 (en) | 1986-06-20 | 1987-12-30 | Shacknai Jonah | Oral sustained release medicament |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
IT1200217B (it) | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
SE8605515D0 (sv) | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A liquid dosage form for oral administration of a pharmaceutically active substance |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
ES2061623T3 (es) | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4902513A (en) * | 1987-07-31 | 1990-02-20 | Jean Carvais | Oral sustained release medicament |
US4837031A (en) | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
US4961932A (en) | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
DE3810757A1 (de) | 1988-03-30 | 1989-10-26 | Freudenberg Carl Fa | Verfahren zur herstellung einer mikroporoesen folie |
US5268182A (en) | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
FR2634377B1 (fr) | 1988-06-30 | 1991-09-27 | Cortial | Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif |
US5028434A (en) | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
IT1226940B (it) * | 1988-09-16 | 1991-02-22 | Recordati Chem Pharm | Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide |
FI894611A (fi) | 1988-09-30 | 1990-03-31 | May & Baker Ltd | Granulaera farmaceutiska preparat. |
US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
US5186930A (en) * | 1988-11-14 | 1993-02-16 | Schering Corporation | Sustained release oral suspensions |
IT1227899B (it) * | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
FR2642080B1 (fr) | 1989-01-23 | 1992-10-02 | Onera (Off Nat Aerospatiale) | Polysilanes et leur procede de preparation |
US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5084278A (en) | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
AU632602B2 (en) | 1989-08-02 | 1993-01-07 | John David Arnold | Method and preparation for reducing risk of myocardial infarction |
NZ233975A (en) | 1989-08-16 | 1992-06-25 | Sterling Drug Inc | Aspirin granules coated with a gastroprotectant |
IT1256651B (it) | 1992-12-11 | 1995-12-12 | Giancarlo Santus | Composizione farmaceutica a rilascio controllato in sospensione liquida |
JP2571874B2 (ja) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | タンパク質マイクロスフェア組成物 |
AU634606B2 (en) | 1989-11-06 | 1993-02-25 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5248516A (en) | 1989-12-19 | 1993-09-28 | Fmc Corporation | Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like |
GB9002495D0 (en) | 1990-02-05 | 1990-04-04 | Monsanto Europe Sa | Glyphosate compositions |
US5206030A (en) | 1990-02-26 | 1993-04-27 | Fmc Corporation | Film-forming composition and use for coating pharmaceuticals, foods and the like |
IT1246383B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
WO1991019486A1 (en) | 1990-06-14 | 1991-12-26 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
CA2083606C (en) | 1990-06-20 | 2001-08-21 | Arne Elof Brandstrom | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
WO1992001446A1 (en) | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
SE9002684D0 (sv) | 1990-08-17 | 1990-08-17 | Malvac Foundation C O Peter Pe | New peptides and their use |
EP0477135A1 (en) | 1990-09-07 | 1992-03-25 | Warner-Lambert Company | Chewable spheroidal coated microcapsules and methods for preparing same |
GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5219895A (en) | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
FI922107A0 (fi) | 1991-05-10 | 1992-05-08 | Faulding F H & Co Ltd | Mikrokapselkomposition och foerfarande. |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
DE69220317T2 (de) | 1991-10-01 | 1997-10-16 | Takeda Chemical Industries Ltd | Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5409709A (en) | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
US5571533A (en) | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
US5286495A (en) | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
IL103224A (en) | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
WO1994009762A1 (en) | 1992-11-05 | 1994-05-11 | Merck & Co., Inc. | Drug delivery device |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
FR2708932B1 (fr) | 1993-08-10 | 1995-11-10 | Flamel Tech Sa | Procédé de préparation de polyaminoacides. |
HU218673B (hu) | 1993-10-07 | 2000-10-28 | Euroceltique S.A. | Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
MX9605419A (es) | 1994-05-06 | 1997-12-31 | Pfizer | Formas de dosificacion de liberacion controlada de azitromicina. |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
JPH0873345A (ja) | 1994-09-05 | 1996-03-19 | Terumo Corp | 医薬製剤 |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
FR2724563A1 (fr) | 1994-09-15 | 1996-03-22 | Coletica | Utilisation de membranes collageniques comme protheses de regeneration peritoneale |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5858398A (en) | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
GB9423588D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
KR0167613B1 (ko) | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
JP2690276B2 (ja) | 1995-01-10 | 1997-12-10 | 科学技術振興事業団 | 静電結合型高分子ミセル薬物担体とその薬剤 |
FR2732218B1 (fr) | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
US5750468A (en) | 1995-04-10 | 1998-05-12 | Monsanto Company | Glyphosate formulations containing etheramine surfactants |
US5674529A (en) | 1995-06-06 | 1997-10-07 | Church & Dwight Co., Inc. | Alkalinizing potassium salt controlled release preparations |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
NZ318282A (en) | 1995-09-07 | 2000-01-28 | Smithkline Beecham Corp | Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1 |
DE69636413T2 (de) | 1995-11-13 | 2007-03-29 | North West University | Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
CA2238975A1 (en) | 1995-12-12 | 1997-06-19 | Merck & Co., Inc. | New use for losartan |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
FR2746035B1 (fr) | 1996-03-15 | 1998-06-12 | Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications | |
US20030064108A1 (en) | 1996-04-23 | 2003-04-03 | Stefan Lukas | Taste masked pharmaceutical compositions |
DE19628341C2 (de) * | 1996-07-13 | 1998-09-17 | Sihl Gmbh | Aufzeichnungsmaterial für Tintenstrahlverfahren mit wäßriger Tinte und Verwendung zum Herstellen wasserfester und lichtbeständiger Aufzeichnungen auf diesem Material |
FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
US5780055A (en) | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
AU5101798A (en) | 1996-12-04 | 1998-06-29 | Bristol-Myers Squibb Company | Method for oral administration of buspirone |
WO1998026803A1 (fr) | 1996-12-19 | 1998-06-25 | Daiichi Pharmaceutical Co., Ltd. | Composition pharmaceutique pour administration par voie orale |
FR2759083B1 (fr) | 1997-02-06 | 1999-04-30 | Dev Des Utilisations Du Collag | Materiau collagenique utile notamment pour la prevention d'adherences post-operatoires |
US5981761A (en) | 1997-03-27 | 1999-11-09 | Solutia Inc. | Crosslinked polyaspartate salts a process for their production |
US6162463A (en) | 1997-05-01 | 2000-12-19 | Dov Pharmaceutical Inc | Extended release formulation of diltiazem hydrochloride |
WO1998053680A1 (en) | 1997-05-30 | 1998-12-03 | Monsanto Company | Process and compositions promoting biological effectiveness of exogenous chemical substances in plants |
ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
JP3677156B2 (ja) | 1997-09-05 | 2005-07-27 | 武田薬品工業株式会社 | 医薬 |
WO1999013864A2 (en) | 1997-09-19 | 1999-03-25 | Shire Laboratories, Inc. | Solid solution beadlet |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
FR2771291B1 (fr) | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | Spheroides, procede de preparation et compositions pharmaceutiques |
US6444246B1 (en) | 1997-12-16 | 2002-09-03 | Mccormick & Company, Inc. | Cake-resistant, hygroscopically sensitive materials and process for producing the same |
BR9813826A (pt) | 1997-12-22 | 2000-10-10 | Euro Celtique Sa | Potencial de uso abusivo de administração oral de opióide analgésico |
SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
NZ506202A (en) | 1998-03-19 | 2003-10-31 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
YU51300A (sh) | 1998-03-20 | 2002-09-19 | Cowa Co. Ltd. | Adhezivna farmaceutska kompozicija za želudac i/ili dvanaestopalačno crevo |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
IL138765A0 (en) | 1998-03-30 | 2001-10-31 | Rtp Pharma Inc | Compositions containing microparticles of water-insoluble substances and method for their preparation |
US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
DK0974356T3 (da) | 1998-07-15 | 2003-10-27 | Merck Sante Sas | Tabletter omfattende en kombination af metformin og glibenclamid |
CA2338780C (en) | 1998-07-28 | 2007-01-02 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing medicinal substance at targeted site in intestine |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
US6179862B1 (en) | 1998-08-14 | 2001-01-30 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
AU6283299A (en) | 1998-10-01 | 2000-04-17 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
JP2000128774A (ja) | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | 薬物を含有する球形微粒子の製法 |
WO2000025752A1 (en) | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
NZ511614A (en) | 1998-11-12 | 2003-12-19 | Smithkline Beecham P | Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin |
FR2786098B1 (fr) | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
DE19860698A1 (de) | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
JP3645816B2 (ja) | 1999-02-23 | 2005-05-11 | ユハン・コーポレーション | ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
AU767177B2 (en) | 1999-04-13 | 2003-11-06 | Beecham Pharmaceuticals (Pte) Limited | Novel method of treatment |
US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
SE9902386D0 (sv) | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
WO2001008661A2 (en) | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
NZ517559A (en) * | 1999-08-31 | 2004-08-27 | Gruenenthal Chemie | Sustained release pharmaceutical composition containing tramadol saccharinate |
ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
US6264983B1 (en) | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
CO5200844A1 (es) | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
HU229352B1 (en) | 1999-11-03 | 2013-11-28 | Bristol Myers Squibb Co | Medicament comprising the combination of metformin and glyburide |
FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
DE19961897A1 (de) * | 1999-12-20 | 2001-06-28 | Basf Ag | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
US7785625B2 (en) | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
SI1299104T1 (sl) | 2000-02-08 | 2009-10-31 | Euro Celtique Sa | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
AU2001232020A1 (en) | 2000-02-09 | 2001-08-20 | West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited | Floating drug delivery composition |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6951534B2 (en) | 2000-06-13 | 2005-10-04 | Acorn Cardiovascular, Inc. | Cardiac support device |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
JP2002003366A (ja) | 2000-06-23 | 2002-01-09 | Freunt Ind Co Ltd | 固形薬剤用水系コーティング剤組成物 |
KR100496749B1 (ko) | 2000-07-05 | 2005-06-22 | 아사히 가세이 가부시키가이샤 | 셀룰로스 분말 |
FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7074417B2 (en) | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US6499158B1 (en) | 2000-10-30 | 2002-12-31 | Steris, Inc. | Surgical table top and accessory clamp used thereon |
FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
ATE425731T1 (de) | 2000-12-28 | 2009-04-15 | Tap Pharmaceutical Prod Inc | Pharmazeutische zusammensetzungen eines nichtmagensaftresistenten protonenpumpen-hemmers mit einer carbonat- und bicarbonatsalzkombination |
AU2002257582A1 (en) | 2001-02-14 | 2002-09-04 | Glaxo Wellcome S.A. | Pharmaceutical formulation |
CA2440069A1 (en) * | 2001-03-05 | 2002-09-12 | Ortho-Mcneil Pharmaceutical, Inc. | Taste masked pharmaceutical compositions |
FR2821745B1 (fr) | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Granules et granules enrobes au gout masque |
BR0102252B1 (pt) | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
WO2002085335A1 (en) | 2001-04-18 | 2002-10-31 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
GB0114532D0 (en) | 2001-06-14 | 2001-08-08 | Jagotec Ag | Novel compositions |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
KR20040060917A (ko) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
IL160217A0 (en) | 2001-08-06 | 2004-07-25 | Euro Celtique Sa | Compositions and methods to prevent abuse of opioids |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
EP1418886A1 (de) | 2001-08-10 | 2004-05-19 | Beiersdorf AG | Kosmetische reinigungsrezepturen auf basis einer kombination von natriumlaurethsulfat und alkylpolyamphopolycarboxyglycinaten |
US20030083286A1 (en) | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20030099711A1 (en) * | 2001-08-29 | 2003-05-29 | David Meadows | Sustained release preparations |
US20030050620A1 (en) | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
FR2830447B1 (fr) | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
GB0124459D0 (en) | 2001-10-11 | 2001-12-05 | Novartis Ag | Organic compounds |
JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030104052A1 (en) | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20040126428A1 (en) | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
FR2837100B1 (fr) | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
WO2003080069A1 (en) | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent |
US20050089572A1 (en) | 2002-03-22 | 2005-04-28 | Manoj Kumar | Controlled release drug delivery system of pravastatin |
US7790215B2 (en) | 2002-03-26 | 2010-09-07 | Purdue Pharma Lp | Sustained-release gel coated compositions |
WO2003084517A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules d’amoxicilline |
PT1492511E (pt) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s) |
US20050106249A1 (en) | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
WO2003094899A1 (es) | 2002-05-09 | 2003-11-20 | Diffucap-Chemobras Química E Farmacéutica, Ltda. | Nuevo procedimiento para la preparacion de composiciones de liberacion programada conteniendo (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, y al producto obtenido por dicho procedimiento |
AU2003229005A1 (en) | 2002-05-10 | 2003-11-11 | Merck And Co., Inc. | Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events |
AU2003245345A1 (en) | 2002-05-31 | 2003-12-19 | Alza Corporation | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
US7771707B2 (en) | 2004-06-12 | 2010-08-10 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
WO2004004693A1 (en) | 2002-07-05 | 2004-01-15 | Collgegium Pharmaceutical | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
NZ520149A (en) | 2002-07-12 | 2003-01-31 | Reinforced Concrete Pipes Pty | Anchoring device |
US20040208936A1 (en) | 2002-07-22 | 2004-10-21 | Roland Chorin | Novel compositions |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
FR2843117B1 (fr) | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques |
US6727839B2 (en) | 2002-08-23 | 2004-04-27 | Broadcom Corporation | High speed, low power comparator |
US7538094B2 (en) | 2002-09-19 | 2009-05-26 | Three Rivers Pharmacueticals, Llc | Composition containing ribavirin and use thereof |
JP5189242B2 (ja) | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | 乱用抵抗性の医薬組成物 |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
JP2004188307A (ja) | 2002-12-11 | 2004-07-08 | Japan Atom Energy Res Inst | リン酸基を有するジルコニウム担持繊維状吸着材の合成方法、及びそれを用いたヒ素の除去 |
BR0317275A (pt) | 2002-12-11 | 2005-11-08 | Pfizer Prod Inc | Liberação controlada de uma substância ativa em um ambiente de gordura alta |
JP4865330B2 (ja) | 2002-12-13 | 2012-02-01 | デュレクト コーポレーション | 経口ドラッグデリバリーシステム |
AU2003301121A1 (en) | 2002-12-18 | 2004-07-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
US20060210620A1 (en) | 2003-01-21 | 2006-09-21 | Kumra Pannanchukunnath M | Co-precipitated amorphous losartan and dosage forms comprising the same |
WO2004087175A1 (en) | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
PT2279729T (pt) | 2003-07-17 | 2016-09-22 | Banner Life Sciences Llc | Preparações de libertação controlada |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
NZ545202A (en) | 2003-08-06 | 2010-03-26 | Gruenenthal Chemie | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide |
ZA200601181B (en) | 2003-08-13 | 2007-04-25 | Smith Howard J & Ass Pty Ltd | Method of treating viral infections |
US7470435B2 (en) | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
AU2005259478B2 (en) | 2004-07-01 | 2010-07-15 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
PL1811979T3 (pl) | 2004-09-27 | 2009-04-30 | Sigmoid Pharma Ltd | Mikrokapsułki zawierające metyloksantynę i kortykosteroid |
CA2581002C (en) | 2004-10-15 | 2012-01-10 | Supernus Pharmaceuticals, Inc. | Less abusable pharmaceutical preparations |
FR2878161B1 (fr) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
FR2878158B1 (fr) | 2004-11-24 | 2009-01-16 | Flamel Technologies Sa | Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage |
FR2889810A1 (fr) | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
US20070166378A1 (en) * | 2005-06-09 | 2007-07-19 | Flamel Technologies, Inc. | Oral ribavirin pharmaceutical compositions |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
FR2892937B1 (fr) | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
-
2003
- 2003-04-07 PT PT03745832T patent/PT1492511E/pt unknown
- 2003-04-07 CN CNB038105284A patent/CN100553625C/zh not_active Expired - Lifetime
- 2003-04-07 AU AU2003246792A patent/AU2003246792B2/en not_active Expired
- 2003-04-07 EP EP03745832A patent/EP1492511B3/fr not_active Expired - Lifetime
- 2003-04-07 DE DE60325709T patent/DE60325709D1/de not_active Expired - Lifetime
- 2003-04-07 ES ES03745832T patent/ES2320438T7/es active Active
- 2003-04-07 WO PCT/FR2003/001096 patent/WO2003084518A2/fr active Application Filing
- 2003-04-07 JP JP2003581758A patent/JP4732696B2/ja not_active Expired - Lifetime
- 2003-04-07 KR KR1020047016079A patent/KR101061351B1/ko active IP Right Grant
- 2003-04-07 BR BRPI0309142A patent/BRPI0309142C1/pt not_active IP Right Cessation
- 2003-04-07 CA CA2480826A patent/CA2480826C/fr not_active Expired - Lifetime
- 2003-04-07 MX MXPA04009968A patent/MXPA04009968A/es active IP Right Grant
- 2003-04-07 AT AT03745832T patent/ATE419840T1/de active
- 2003-04-07 US US10/510,643 patent/US7906145B2/en active Active
- 2003-04-07 IL IL16422203A patent/IL164222A0/xx unknown
-
2004
- 2004-09-22 IL IL164222A patent/IL164222A/en active IP Right Grant
-
2005
- 2005-12-17 HK HK05111660.1A patent/HK1079448A1/xx not_active IP Right Cessation
-
2011
- 2011-01-26 US US13/014,137 patent/US10004693B2/en not_active Expired - Lifetime
-
2015
- 2015-09-09 US US14/848,699 patent/US9814684B2/en not_active Expired - Lifetime
- 2015-09-09 US US14/848,603 patent/US20150374635A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,727 patent/US20170281558A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101061351B1 (ko) | 활성 성분 마이크로캡슐의 경구 현탁액 | |
US10568832B2 (en) | Taste-masked pharmaceutical compositions | |
RU2428176C2 (ru) | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты | |
US5670172A (en) | Pharmaceutical spheroid formulation | |
US20110129539A1 (en) | Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for modified release of amoxicillin | |
EP0239361A1 (en) | Sustained-release pharmaceutical preparation | |
CA2992356C (en) | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form | |
JP2005506336A (ja) | 薬学的活性成分の遅延かつ制御された放出のための微小粒子経口ガレヌス製剤形態 | |
KR20050026515A (ko) | 저용해도를 갖는 활성 성분의 연장 방출을 위한 다수의마이크로캡슐 형태의 경구 약학 제형 | |
US20060159758A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
CN102046155A (zh) | 包含多颗粒的具有双重释放特性的固体口服剂型 | |
KR20220113697A (ko) | 알칼리제 및 장용성 코팅층을 포함하는 투여 형태 | |
EP3117824A1 (en) | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form | |
ZA200407594B (en) | Oral suspension of active principle microcapsules | |
BR122013000700B1 (pt) | "suspension microcapsules in a net stage aquasa" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140725 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150727 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160725 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170726 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180725 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190725 Year of fee payment: 9 |